Abstract:Background While China has implemented reimbursement-linked drug price negotiation annually since 2017, emphasizing value-based pricing to achieve a value-based strategic purchase of medical insurance, whether drug prices became better aligned with clinical value after price negotiation has not been sufficiently established. This study aimed to assess the changes in prices and their relationship with the clinical value of anticancer drugs after the implementation of price negotiations in China. Methods and findings In this observational study, anticancer drug indications that were negotiated successfully between 2017 and 2022 were identified through National Reimbursement Drug Lists (NRDL) of China. We excluded extensions of indications for drugs already listed in the NRDL, indications for pediatric use, and indications lacking corresponding clinical trials. We identified pivotal clinical trials for included indications by consulting review reports or drug labels issued by the Center for Drug Evaluation, National Medical Products Administration. We calculated treatment costs as outcome measures based on publicly available prices and collected data on clinical value including safety, survival, quality of life, and overall response rate (ORR) from publications of pivotal clinical trials. The associations between drug costs and clinical value, both before and after negotiation, were analyzed using regression analyses. We also examined whether price negotiation has led to a reduction in the variation of treatment costs for a given value. We included 103 anticancer drug indications, primarily for the treatment of blood cancer, lung cancer, and breast cancer, with 76 supported by randomized controlled trials and 27 supported by single-arm clinical trials. The median treatment costs over the entire sample have been reduced from US$34,460.72 (interquartile range (IQR): 19,990.49 to 55,441.66) to US$13,688.79 (IQR: 7,746.97 to 21,750.97) after price negotiation ( P < 0.001). Before price negotiation, each additional month of survival gained was associated with an increase in treatment costs of 3.4% (95% confidence interval (CI) [2.1, 4.8], P < 0.001) for indications supported by randomized controlled trials, and a 10% increase in ORR was associated with a 6.0% (95% CI [1.6, 10.3], P = 0.009) increase in treatment costs for indications supported by single-arm clinical trials. After price negotiation, the associations between costs and clinical value may not have changed significantly, but the variation of drug costs for a given value was reduced. Study limitations include the lack of transparency in official data, missing data on clinical value, and a limited sample size. Conclusions In this study, we found that the implementation of price negotiation in China has led to drug pricing better aligned with clinical value for anticancer drugs even after substantial price reductions. The achievements made in China could shed light on the price regulation in other countries, particularly those with limited resources and increasing drug expenditures.

Payer-Negotiated Price Variation and Relationship to Surgical Outcomes for the Most Common Cancers at NCI-Designated Cancer Centers

Variability in expenses related to spine oncology care: comparison of payer-negotiated rates at National Cancer Institute-Designated Cancer Centers

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China

Variation in physician spending and its association with postoperative outcomes among patients undergoing surgery for gastrointestinal cancer

Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery

Assessment of price variation in colorectal cancer screening procedures at US hospitals.

Center-level variation in hospitalization costs of pancreaticoduodenectomy for pancreatic cancer

Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments

Price negotiation and pricing of anticancer drugs in China: An observational study

Financial (dis)incentives to surgical management of head and neck cancer care

Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare

The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China

Assessment of variation in 30-day mortality following cancer surgeries among older adults across US hospitals

Cost drivers of locally advanced rectal cancer treatment-An analysis of a leading healthcare insurer

Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective

114 Compliance with Federal Price Transparency Rules at US Hospitals With Neurosurgical Training Programs

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study

Surgical treatment of liver cancer and pancreatic cancer under the China Healthcare Security Diagnosis Related Groups payment system

Cost‐of‐care discussions for individuals with advanced non–small cell lung cancer and melanoma: Findings from a large, population‐based pilot study

Market Factors, Not Quality, Influence Reimbursement for Pancreaticoduodenectomy in an Era of Price Transparency

Impact of patient choice and hospital competition on patient outcomes after rectal cancer surgery: A national population-based study